|
Dr. Simonian joined Millennium in 2001 as Vice President of Clinical Development and in 2006 was appointed Chief Medical Officer. She is responsible for clinical development, Regulatory affairs, pharmacovigilance and development project management.
Prior to joining Millennium, Dr. Simonian was Vice President of Clinical Research at Biogen, where she was responsible for the clinical development of AVONEX� (Interferon beta-1a), Tysabri (natalizumab) and their oncology programs.
Dr. Simonian earned a bachelor's degree in Biology from Princeton University and received her M.D. from the University of Pennsylvania, School of Medicine. She completed her medical residency at Massachusetts General Hospital (MGH) in Neurology, was an Assistant Clinical Professor at MGH and Harvard Medical School, and is board-certified in Neurology.
Dr. Simonian chairs the Portfolio Review Committee at Millennium. She also is a board member of Arqule Pharmaceuticals. In 1995, Dr. Simonian was awarded the Physician Scientist award from the National Institutes of Health and in 1994 named an Ellison Scholar. In 1988, she was awarded the Academic Medicine, Clinical Medicine and Neurology prizes from the University of Pennsylvania, School of Medicine.
| 